GlassScriptPhysician profile
Melissa Acevedo
NPI 1306157722
$2,305.46
in general payments reported to CMS, 2019-2025
31 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $73.69 · 2021: $291 · 2022: $614 · 2023: $509 · 2024: $289 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.91 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $395.72 | 2021-2025 | |
| Astellas Pharma US INC | $351.64 | 2022-2024 | Veozah, Myrbetriq |
| Gynesonics, INC. | $217.41 | 2022 | |
| Abbvie INC. | $172.57 | 2019-2023 | Liletta |
| Hologic Sales and Service, LLC | $147.81 | 2021-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Pfizer INC. | $127.60 | 2019-2025 | |
| Allergan, INC. | $79.22 | 2019-2020 | |
| Exact Sciences Corporation | $74.34 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $72.99 | 2021-2025 | Solosec, Phexx, Phexxi |
| Myovant Sciences INC. | $60.36 | 2021-2022 | |
| Medicem INC. | $59.45 | 2021-2022 | |
| Biogen, INC. | $54.44 | 2024 | |
| Daiichi Sankyo INC. | $44.83 | 2020-2021 | |
| Therapeuticsmd, INC. | $43.82 | 2021 | |
| Coopersurgical, INC. | $38.55 | 2024-2025 | Paragard T 380a |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.75 | 2019-2020 | |
| Organon LLC | $36.03 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $29.35 | 2019 | |
| Genentech USA, INC. | $26.46 | 2023 | Phesgo |
| Baxter Healthcare | $26.24 | 2025 | Perclot |
| Millicent US INC | $21.91 | 2025 | Femlyv, Intrarosa |
| Mylan Pharmaceuticals INC. | $21.06 | 2022 | |
| Roche Diagnostics Corporation | $20.93 | 2021 | |
| Viiv Healthcare Company | $20.53 | 2024 | Apretude |
| Becton, Dickinson and Company | $19.97 | 2022 | |
| Alydia Health | $19.71 | 2021 | |
| Exeltis, USA INC. | $19.48 | 2023 | Slynd |
| Shield Therapeutics INC | $18.34 | 2024 | |
| Ibsa Pharma INC. | $17.62 | 2023 | Tirosint, Licart |
| Avion Pharmaceuticals | $15.49 | 2023 | Balcoltra |
| Lupin INC. | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Acevedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.